- |||||||||| 6 Mercaptopurine / Teva
[VIRTUAL] Prevention of 6-Mercaptopurine-Induced Hypoglycemia by Levocarnitine Replacement () - Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_1662;
Increase in plasma free fatty acids without expected increase in plasma and urine ketone bodies may be sign of impaired synthesis of carnitine, which is required for transport of fatty acids into the mitochondria to produce ketone bodies. Measuring serum total and free carnitine in hypoglycemia induced by 6-Mercaptopurine is helpful in identifying children, who may benefit from Levocarnitine replacement.
- |||||||||| Clinical, Review, Journal: Paternal safety of anti-rheumatic medications. (Pubmed Central) - Jun 18, 2020
Methotrexate; NSAIDs; glucocorticoids; sulfasalazine; the immunosuppressive agents azathioprine, 6-mercaptopurine, cyclosporine, tacrolimus, and mycophenolate mofetil; colchicine; TNF-alpha blockers; hydroxychloroquine; IVIG; rituximab; abatacept; and anakinra are compatible with paternal exposure. There are insufficient data to conclude the safety of other biologics and small molecules in men seeking to father a child.
- |||||||||| 6 Mercaptopurine / Teva
Journal: Mechanisms of NT5C2-mediated thiopurine resistance in acute lymphoblastic leukemia. (Pubmed Central) - Jun 12, 2020
Expression of mutant NT5C2 mutations also significantly reduced thiopurine uptake in vitro with concomitant increase in efflux of 6-mercaptopurine (MP) metabolites, plausibly via indirect effects on drug transporter pathways...Collectively, our data indicated that NT5C2 mutations alter thiopurine metabolism and cellular disposition, but also influenced endogenous nucleotide homeostasis and thiopurine-induced metabolomic response. These complex mechanisms contributed to NT5C2-mediated drug resistance in ALL and pointed to potential opportunities for therapeutic targeting in relapsed ALL.
- |||||||||| 6 Mercaptopurine / Teva, doxorubicin hydrochloride / Generic mfg.
Journal: A bio-responsive 6-mercaptopurine/doxorubicin based "Click Chemistry" polymeric prodrug for cancer therapy. (Pubmed Central) - Jun 4, 2020
Moreover, the graft ratio of DOX and 6MP showed the ability to adjust the cytotoxicity; the micelles with a graft ratio of 2: 1 (M(DOX/6MP)) displayed the higher cellular inhibition on either HeLa (combination index (CI) = 0.62) or HL-60 (CI = 0.35) cells. Overall, this novel dual-drug-conjugated delivery system might have important potential applications for combination therapy of cancer.
- |||||||||| 6 Mercaptopurine / Teva, azathioprine orodispersible / Generic mfg.
Journal: High-throughput screening of active compounds against human respiratory syncytial virus. (Pubmed Central) - Apr 10, 2020
Further experiments revealed that they functioned by targeting virus transcription or/and genome replication. In conclusion, the established HTS assay is suitable to screen anti-RSV compounds, and the screened two hits of AZA and 6-MP, as potential anti-RSV agents targeting RSV genome replication/transcription, are worthy of further investigation on their anti-RSV activity in vivo.
- |||||||||| methotrexate / Generic mfg., mercaptopurine delayed release (DR6MP) / Teva
Clinical, Journal: Model-Based Simulation of Maintenance Therapy of Childhood Acute Lymphoblastic Leukemia. (Pubmed Central) - Apr 9, 2020
Successful treatment requires initial high-intensity chemotherapy, followed by low-intensity oral maintenance therapy with oral 6-mercaptopurine (6MP) and methotrexate (MTX) until 2-3 years after disease onset...Using the new cross-validated mathematical model, simulations of different treatment protocols showed a linear dose-effect relationship and reduced ANC variability for constant dosages. Advanced modeling allows the identification of optimized control criteria and the weighting of specific influencing factors for protocol design and individually adapted therapy to exploit the optimal effect of maintenance therapy on survival.
- |||||||||| 6 Mercaptopurine / Teva
Biomarker, Clinical, Journal: Screening of Novel Pharmacogenetic Candidates for Mercaptopurine-Induced Toxicity in Patients With Acute Lymphoblastic Leukemia. (Pubmed Central) - Apr 9, 2020
A small proportion of patients with acute lymphoblastic leukemia (ALL) may experience severe leukopenia after treating with 6-mercaptopurine (6MP), which can be largely explained by germline variants in TPMT and NUDT15...In addition, a variant (i.e., rs4680) in COMT is significantly associated with 6MP-induced hepatotoxicity (P = 0.007). In conclusion, variants in CYP2A7 and COMT may be considered as novel potential pharmacogenetic markers for 6MP-induced toxicities, but additional independent validations with large sample size and investigations on related mechanisms are further needed.
- |||||||||| allopurinol / Generic mfg.
SKEWED MERCAPTOPURINE METABOLISM SUCCESSFULLY CORRECTED WITH ALLOPURINOL IN PEDIATRIC LEUKEMIA () - Apr 3, 2020 - Abstract #ASPHO2020ASPHO_349;
Prior gastroenterology publications suggest a much lower incidence of 6-MP metabolite shunting at 15%. The patients who received allopurinol during their treatment period showed reversal of undesired toxicities, suggesting that combination therapy may be beneficial for additional patients.
- |||||||||| Decadron (dexamethasone) / Merck (MSD), sirolimus / Generic mfg.
NEONATAL PRESENTATION OF RAS-ASSOCIATED AUTOIMMUNE LEUKOPROLIFERATIVE DISORDER () - Apr 3, 2020 - Abstract #ASPHO2020ASPHO_258;
This diagnosis should be considered in patients with splenomegaly, autoimmunity, and/or blood count abnormalities such as persistent monocytosis and hematogone hyperplasia which may serve as disease markers. Diagnosis is made with bone marrow evaluation and confirmation of somatic RAS mutation.
- |||||||||| 6 Mercaptopurine / Teva
Journal, IO Biomarker: AOC1 Contributes to Tumor Progression by Promoting the AKT and EMT Pathways in Gastric Cancer. (Pubmed Central) - Mar 28, 2020
Finally, we found that knockdown of AOC1 inhibited the epithelial-mesenchymal transition (EMT) in human gastric cancer by increasing the expression of epithelial markers E-cadherin, as well as decreasing mesenchymal marker N-cadherin, SNAIL and Slug. Our study suggests that AOC1 functions as an oncogene in human gastric cancer by activating the AKT signaling pathway and EMT process and maybe a target of 6-mercaptopurine, which provides new insight in the clinical use of AOC1 in gastric cancer therapy.
- |||||||||| azathioprine orodispersible / Generic mfg.
Preclinical, Journal: Effects of azathioprine and its metabolites on inflammatory cytokines in human nasal polyp organ cultures. (Pubmed Central) - Mar 26, 2020
Our study suggests that AOC1 functions as an oncogene in human gastric cancer by activating the AKT signaling pathway and EMT process and maybe a target of 6-mercaptopurine, which provides new insight in the clinical use of AOC1 in gastric cancer therapy. Topical AZT decreases inflammatory cytokines on human NP explants and this could have future therapeutic implications for NPs.
- |||||||||| 6 Mercaptopurine / Teva
Journal: Effects of 6-mercaptopurine in pressure overload induced right heart failure. (Pubmed Central) - Mar 24, 2020
Treatment with 6-mercaptopurine did not have any beneficial or detrimental effects on right ventricular function or remodelling. Our data suggest that treatment of pulmonary arterial hypertension with 6-mercaptopurine is not harmful to the failing right ventricle.
- |||||||||| etoposide IV / Generic mfg., 6 Mercaptopurine / Teva
A Rare Presentation of Acute Respiratory Distress Syndrome Due to Cytomegalovirus-Induced Hemophagocytic Lymphohistiocytosis (PENNSYLVANIA CONVENTION CENTER, Hall D-E (200 Level), Area A) - Mar 15, 2020 - Abstract #ATS2020ATS_9724;
Following this diagnosis, she was continued on high doses of systemic corticosteroids and treated with etoposide, with eventual improvement and recovery.Our case demonstrates inflammatory bowel disease and 6-mercaptopurine as risk factors for the development CMV-induced HLH, presenting with ARDS. Although several previous case reports have indicated a correlation between inflammatory bowel disease (IBD) and HLH, our case demonstrates an uncommon, severe presentation.
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
Intestinal Tuberculosis Mimics Crohn'S Disease. Diagnostic and Therapeutic Challenge. A Case Series (PENNSYLVANIA CONVENTION CENTER, Hall D-E (200 Level), Area J) - Mar 15, 2020 - Abstract #ATS2020ATS_5900;
Although there are radiological, endoscopic and histological criteria that have been recommended for diagnosis of CD, intestinal TB can mimic CD findings and differentiation is difficult in clinical practice.CASE SERIES:Case 1:58 year-old male originally from Philippines who presented with bloody diarrhea and cramping, after workup by gastroenterologist, was diagnosed with CD and treated with 6-mercaptopurine and steroids...Humira was started bi-weekly but abdominal pain and bloody diarrhea continued...Diagnosed with CD and started in prednisone...TB should be considered in adults from endemic areas who present with chronic diarrhea when Prometheus studies are negative. Patients from endemic areas would benefit from further testing to rule out TB by MTB/PCR or AFB smear/culture.
- |||||||||| Remicade (infliximab) / Mitsubishi Tanabe, J&J
Necrobiotic Mass in Crohn's Disease: A Case Report (PENNSYLVANIA CONVENTION CENTER, Hall D-E (200 Level), Area A) - Mar 15, 2020 - Abstract #ATS2020ATS_5057;
While necrobiotic inflammation should be recognized as a potential cause of pulmonary nodules and masses in Crohn’s disease, this should be a viewed as a diagnosis of exclusion and only established after thorough workup to exclude infectious, vasculitic, and neoplastic etiologies. This case demonstrates that regression of a necrobiotic pulmonary mass can be anticipated by treating the underlying Crohn’s disease with intensified immunosuppressive treatment.
- |||||||||| 6 Mercaptopurine / Teva
THE REGULATION OF INTESTINAL SMOOTH MUSCLE CELL PROLIFERATION IN CROHN’S DISEASE – IS NR4A1 A NOVEL TARGET TO TREAT FIBROSTENOSIS? () - Mar 8, 2020 - Abstract #CDDW2020CDDW_32;
In mouse and human SMCs, proliferation was induced by platelet-derived growth factor-BB (PDGF-BB) and NR4A1 activation was assessed by pretreating with selective agonists, cytosporone B (Csn-B) and 6-mercaptopurine (6-MP), at various concentrations...These data support targeting NR4A1 to treat excessive smooth muscle hypertrophy/hyperplasia that contributes to tissue remodelling observed in fibrostenotic CD. Funding Agencies CAG, CCC, CIHR
- |||||||||| methotrexate / Generic mfg., 6 Mercaptopurine / Teva, azathioprine orodispersible / Generic mfg.
Review, Journal: Allergic and Immunologic Perspectives of Inflammatory Bowel Disease. (Pubmed Central) - Feb 29, 2020
Our knowledge and understanding of IBD has grown significantly. However, there are several unanswered questions on pathogenesis, disease behavior, and drivers of inflammation in various patient subgroups which require further research.
- |||||||||| 6 Mercaptopurine / Teva, azathioprine orodispersible / Generic mfg.
Biomarker, Review, Journal: Biomarkers Predictive of Response to Thiopurine Therapy in Inflammatory Bowel Disease. (Pubmed Central) - Feb 19, 2020
We further provide a deeper insight into the utility of monitoring the thiopurine treatment by thiopurine metabolites or alternative hematologic parameters. In light of multiple recent publications of biomarkers and biological therapy, our focus in this review is predicting response to thiopurine treatment only, that is, Azathioprine and 6-Mercaptopurine.
- |||||||||| 6 Mercaptopurine / Teva
Clinical, Journal: Effect of NUDT15 on Incidence of Neutropenia in Children with Acute Lymphoblastic Leukemia. (Pubmed Central) - Feb 14, 2020
TPMT and ITPA variants cumulatively are excellent predictors of 6-MP-mediated toxicity. Patients harboring the CT/TT polymorphism of NUDT15 had a significantly higher incidence of neutropenia during the first 3 months of maintenance, resulting in significantly lower doses of 6-MP.
- |||||||||| 6 Mercaptopurine / Teva
Journal: Investigation on absorption and release of mercaptopurine anticancer drug from modified polylactic acid as polymer carrier by molecular dynamic simulation. (Pubmed Central) - Feb 14, 2020
The absorption and release of 6-mercaptopurine anticancer drug was investigated in biodegradable and biocompatible polymer of polylactic acid (PLA) using molecular dynamics simulation...Finally, polyethylene glycol (PEG) polymer with different percentages (10-30 wt%) was used to modify PLA carrier. The simulation results show that the rate of drug release increases by increasing the concentration of PEG polymer in the modified PLA carrier and also with increasing the percentage of drug loaded in the carrier and also the optimum weight percentage of PEG in modified PLA carrier for 35.8 wt% of drug concentration is 11 wt% and the rate of drug release is slower and equal to 4.4 molecules/ns.
- |||||||||| 6 Mercaptopurine / Teva
Prevention of 6-Mercaptopurine-Induced Hypoglycemia by Levocarnitine Replacement (ENDOExpo) - Feb 7, 2020 - Abstract #ENDO2020ENDO_3259;
Increase in plasma free fatty acids without expected increase in plasma and urine ketone bodies may be sign of impaired synthesis of carnitine, which is required for transport of fatty acids into the mitochondria to produce ketone bodies. Measuring serum total and free carnitine in hypoglycemia induced by 6-Mercaptopurine is helpful in identifying children, who may benefit from Levocarnitine replacement.
- |||||||||| Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: Regional Variations in the Use of Biologics and Immunomodulators among Korean Patients with Inflammatory Bowel Diseases. (Pubmed Central) - Jan 30, 2020
Assessment of dynamical properties of 6-mercaptopurine in the presence of EF with various strengths reveals that the applied electric field can act as a trigger on liberation behavior of drug from the porous nanostructure. Regional variation exists in medication prescription rates within a single city as well as nationwide, suggesting that standardization of IBD treatment is necessary in Korea.
|
